Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 7Hematologic Diseases 7Immunoproliferative Disorders 6Lymphoma, Non-Hodgkin 5Lymphatic Diseases 5Lymphoma 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Vascular Diseases 2Paraproteinemias 2Hemostatic Disorders 2Hemorrhagic Disorders 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × dacetuzumab × Clear all
NCT00103779 2014-12-18

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Seagen Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡